

LITERATÚRA

1. Ni She R, Filan PM. Trisomy 21– incidence and outcomes in the first year, in Ireland today. *Ir Med J*. 2014;107(8):248-249.
2. de Graaf G, Buckley F, Skotko BG. Estimation of the number of people with Down syndrome in Europe. *Eur J Hum Genet*. 2021;29(3):402-410.
3. Ďurdíková V, Ďurdík P, Bánovčin P. Pridružené ochorenia u detí s Downovým syndrómom. *Pediatr*. 2008;3(6):338-342.
4. Huggard D, Doherty DG, Molloy EJ. Immune Dysregulation in Children With Down Syndrome. *Front Pediatr* [Internet]. 2020;8. [cit. 2022-03-07] Available from: <https://www.frontiersin.org/article/10.3389/fped.2020.00073>.
5. Lee YI, Peng CC, Chiu NC, et al. Risk factors associated with death in patients with severe respiratory syncytial virus infection. *J Microbiol Immunol Infect*. 2016;49(5):737-742.
6. Garrison MM, Jeffries H, Christakis DA. Risk of Death for Children with Down Syndrome and Sepsis. *J Pediatr*. 2005;147(6):748-52.
7. Kusters MA, Bok VLA, Bolz WEA, et al. Influenza A/H1N1 vaccination response is inadequate in down syndrome children when the latest cut-off values are used. *Pediatr Infect Dis J*. 2012;31(12):1284-1285.
8. Illouz T, Biragyn A, Frenkel-Morgenstern M, et al. Specific Susceptibility to COVID-19 in Adults with Down Syndrome. *Neuromolecular Med*. 2021;23(4):561-571.
9. Alsubie HS, Rosen D. The evaluation and management of respiratory disease in children with Down syndrome (DS). *Paediatr Respir Rev*. 2018;26:49-54.
10. Ram G, Chinen J. Infections and immunodeficiency in Down syndrome. *Clin Exp Immunol*. 2011;164(1):9-16.
11. Uhliarová B, Švec M. Dieťa s Downovým syndrómom v ambulancii ORL lekára. *Pediatr*. 2017;12(2):79-82.
12. Eijsvoogel NB, Versteegen RHJ, van Well GTJ, et al. Increased rate of respiratory symptoms in children with Down syndrome: a 2-year web-based parent-reported prospective study. *Eur J Pediatr*. 2022;181(12):4079-4089.
13. Weijerman ME, Brand PLP, van Furth MA, et al. Recurrent wheeze in children with Down syndrome: is it asthma? *Acta Paediatr*. 2011;100(11):e194-197.
14. Perluigi M, Di Domenico F, Buttterfield DA. Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: Insights from proteomics. *PROTEOMICS – Clin Appl*. 2014;8(1-2):73-85.
15. Huggard D, Kelly L, Ryan E, et al. Increased systemic inflammation in children with Down syndrome. *Cytokine*. 2020;127:154938.
16. Pako J, Bikov A, Karlocai K, et al. Plasma VEGF levels and their relation to right ventricular function in pulmonary hypertension. *Clin Exp Hypertens*. 2015;37(4):340-344.
17. Chotsampancharoen T, Chavananon S, Sripornsawan P, et al. Transient abnormal myelopoiesis in Down syndrome: Experience of long term follow up from a single tertiary center in Thailand. *Pediatr Hematol Oncol*. 2023;40(2):108-116.
18. Schoch J, Rohrer TR, Kaestner M, et al. Quantitative, Phenotypic, and Functional Characterization of Cellular Immunity in Children and Adolescents With Down Syndrome. *J Infect Dis*. 2017;215(10):1619-1628.
19. Marcovecchio GE, Bortolomai I, Ferrua F, et al. Thymic Epithelium Abnormalities in DiGeorge and Down Syndrome Patients Contribute to Dysregulation in T Cell Development. *Front Immunol*. 2019;10:447.
20. Buc M. Heterogenita lymfocytov ako ústredných operačných jednotiek imunitného systému. *Vnitr Lékařství*. 2019;65(2):86-97.
21. Rueda N, Flórez J, Martínez-Cué C. Apoptosis in Down's syndrome: lessons from studies of human and mouse models. *Apoptosis Int J Program Cell Death*. 2013;18(2):121-134.
22. Huggard D, McGrane F, Lagan N, et al. Altered endotoxin responsiveness in healthy children with Down syndrome. *BMC Immunol*. 2018;19(1):31.
23. Chung H, Green PHR, Wang TC, et al. Interferon-Driven Immune Dysregulation in Down Syndrome: A Review of the Evidence. *J Inflamm Res*. 2021;14:5187-5200.
24. Khocht A, Russell B, Cannon JG, et al. Oxidative burst intensity of peripheral phagocytic cells and periodontitis in Down syndrome. *J Periodontol Res*. 2014;49(1):29-35.
25. Bloemers BLP, van Bleek GM, Kimpen JLL, et al. Distinct abnormalities in the innate immune system of children with Down syndrome. *J Pediatr*. 2010;156(5):804-9, 809.e1-809.e5.
26. Cossarizza A, Ortolani C, Forti E, et al. Age-related expansion of functionally inefficient cells with markers of natural killer activity in Down's syndrome. *Blood*. 1991;77(6):1263-1270.
27. Satgé D, Seidel MG. The Pattern of Malignancies in Down Syndrome and Its Potential Context With the Immune System. *Front Immunol*. 2018;9:3058.
28. Li YY, Alexandrov PN, Pogue AI, et al. miRNA-155 upregulation and complement factor H deficits in Down's syndrome. *Neuroreport*. 2012;23(3):168-173.
29. Veteleanu A, Pape S, Davies K, et al. Complement dysregulation and Alzheimer's disease in Down syndrome. *Alzheimer's Dement J Alzheimer's Assoc*. 2022. <https://doi.org/10.1002/alz.12799>.
30. Fitzgerald KA, Kagan JC. Toll-like Receptors and the Control of Immunity. *Cell*. 2020;180(6):1044-1066.
31. Huggard D, Koay WJ, Kelly L, et al. Altered Toll-Like Receptor Signaling in Children with Down Syndrome. *Mediators Inflamm*. 2019;2019:4068734.
32. Huggard D, Molloy EJ. Question 1: Palivizumab for all children with Down syndrome? *Arch Dis Child*. 2019;104(1):94-97.
33. Gutfraind A, Galvani AP, Meyers LA. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection. *JAMA Pediatr*. 2015;169(4):341-348.
34. Kimura T, Takeuchi M, Kawakami K. Utilization and efficacy of palivizumab for children with Down syndrome. *Pediatr Int Off J Jpn Pediatr Soc*. 2020;62(6):677-682.
35. Huggard D, Molloy EJ. Question 1: Do children with Down syndrome benefit from extra vaccinations? *Arch Dis Child*. 2018;103(11):1085-1087.
36. Espinosa JM. Down Syndrome and COVID-19: A Perfect Storm? *Cell Rep Med*. 2020;1(2):100019.
37. Hüls A, Feany PT, Zisman SI, et al. COVID-19 Vaccination of Individuals with Down Syndrome – Data from the Trisomy 21 Research Society Survey on Safety, Efficacy, and Factors Associated with the Decision to Be Vaccinated. *Vaccines*. 2022;10(4):530.
38. Cao C, Wang J, Li Y, et al. Efficacy and safety of OM-85 in paediatric recurrent respiratory tract infections which could have a possible protective effect on COVID-19 pandemic: A meta-analysis. *Int J Clin Pract*. 2021;75(5):e13981.
39. Marseglia GL, Benazzo M, Biasci P, et al. OM-85 in the prevention of respiratory infections: State-of-the-art and future perspectives in clinical practice. *J Biol Regul Homeost Agents*. 2021;35(3):847-863.
40. Luan H, Zhang Q, Wang L, et al. OM85-BV Induced the Productions of IL-1β, IL-6, and TNF-α via TLR4- and TLR2-Mediated ERK1/2/NF-κB Pathway in RAW264.7 Cells. *J Interferon Cytokine Res*. 2014;34(7):526-536.
41. Chia E, Clark A, Flynn B, et al. P549 Should children with down syndrome receive prophylactic antibiotics to prevent recurrent respiratory infections? *Arch Dis Child*. 2019;104(Suppl 3):A373-A373.
42. Huggard D, Kelly L, Worrall A, et al. Melatonin as an immunomodulator in children with Down syndrome. *Pediatr Res*. 2022;91(7):1812-1820.
43. Saghadzadeh A, Mahmoudi M, Dehghani Ashkezari A, et al. Systematic review and meta-analysis shows a specific micronutrient profile in people with Down Syndrome: Lower blood calcium, selenium and zinc, higher red blood cell copper and zinc, and higher salivary calcium and sodium. *PLoS One*. 2017;12(4):e0175437.
44. Stagi S, Lapi E, Romano S, et al. Determinants of Vitamin D Levels in Children and Adolescents with Down Syndrome. *Int J Endocrinol*. 2015;2015:896758.

Pediatrie pro praxi

www.pediatriepropraxi.cz

